As­cendis wins ap­proval for once-week­ly growth hor­mone drug as Pfiz­er, Op­ko Health keep up the pres­sure

Den­mark’s As­cendis Phar­ma won its first FDA ap­proval Wednes­day af­ter­noon, beat­ing out a ri­val pro­gram at Pfiz­er for pe­di­atric growth hor­mone de­fi­cien­cy.

As­cendis notched the OK for lon­apeg­so­ma­t­ropin, to be mar­ket­ed as Skytro­fa, as the first once-week­ly treat­ment for chil­dren aged one and old­er who don’t pro­duce enough growth hor­mone and weigh at least 11.5 kilo­grams, the biotech an­nounced. There’s no in­fo on the pric­ing yet and End­points News has reached out for com­ment, but CEO Jan Møller Mikkelsen said on a con­fer­ence call Wednes­day the cost will be “re­spon­si­ble.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER